Pentoxifylline in COVID-19 and considerations for its research in long COVID.

ABSTRACT:

Introduction

Pentoxifylline (PTX) affects most blood components and the blood vessels, potentially modulating various conditions. Due to its impact on markers linked to COVID-19 severity, research has explored PTX for acute COVID-19. Following the widespread administration of COVID-19 vaccinations, there has been a notable and consistently growing increase in research focusing on long COVID. Consequently, our examination of relevant acute COVID-19 data shall additionally be contextualized into long COVID research.

Methods

Various Databases were searched until July 2024 for all primary clinical studies on Pentoxifylline (PTX) in COVID-19.

Results

Studies were on acute infection with SARS-CoV-2 where PTX was an adjuvant to standard therapy for ethical and practical reas

SUBMITTER: Ramzi A 

PROVIDER: S-EPMC11632036 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature